Chronic hepatitis C (non-A, non-B hepatitis) is a common and often progressive viral liver disease. To assess the efficacy of therapy with the antiviral agent interferon alfa, we randomly assigned 166 patients with chronic hepatitis C to treatment with either 3 million or 1 million units of recombinant interferon alfa three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after six months of interferon therapy was 46 percent in patients treated with 3 million units of interferon (P less than 0.001) and 28 percent in those treated with 1 million units (P less than 0.02), but only 8 percent in untreated patients. The serum alanine aminotransferase level became completely normal in 22 of the 26 patients (85 percent) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56 percent) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histologic improvement because of the regression of lobular and periportal inflammation. Relapse within six months after the completion of treatment occurred in 51 percent of the patients treated with 3 million units of interferon and 44 percent of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.
Khader, Y. S., Dweek, A., Alkafajei, A., Rabi', A. Z.
(2006). Combination Therapy of Interferon and Ribavirin Versus Interferon Monotherapy in Treatment of Chronic Hepatitis C: A Meta-analysis of Clinical Trials. Journal of Pharmacy Practice
19: 265-274
[Abstract]
Mistler, L. A., Brunette, M. F., Marsh, B. J., Vidaver, R. M., Luckoor, R., Rosenberg, S. D.
(2006). Hepatitis C treatment for people with severe mental illness.. Psychosomatics
47: 93-107
[Abstract][Full Text]
Wang, C.-Q., Li, Y., Douglas, S. D., Wang, X., Metzger, D. S., Zhang, T., Ho, W.-Z.
(2005). Morphine Withdrawal Enhances Hepatitis C Virus Replicon Expression. Am. J. Pathol.
167: 1333-1340
[Abstract][Full Text]
Moorman, J., Saad, M., Kosseifi, S., Krishnaswamy, G.
(2005). Hepatitis C Virus and the Lung: Implications for Therapy. Chest
128: 2882-2892
[Abstract][Full Text]
Pudi, R., Ramamurthy, S. S., Das, S.
(2005). A Peptide Derived from RNA Recognition Motif 2 of Human La Protein Binds to Hepatitis C Virus Internal Ribosome Entry Site, Prevents Ribosomal Assembly, and Inhibits Internal Initiation of Translation. J. Virol.
79: 9842-9853
[Abstract][Full Text]
Tsiodras, S., Drimala, P., Stavreas, N., Dachlythras, M., Alamani, A. M., Naoum, G.
(2005). Uterine Sarcoidosis Potentially Associated With Interferon-{alpha} Use for Chronic Hepatitis C Infection. Obstet Gynecol
105: 1198-1201
[Abstract][Full Text]
Yovtcheva, S. P., Rifai, M. A., Moles, J. K., Van Der Linden, B. J.
(2005). Psychiatric Comorbidity Among Hepatitis C-Positive Patients. Focus
3: 261-265
[Abstract][Full Text]
Takahashi, M., Saito, H., Higashimoto, M., Atsukawa, K., Ishii, H.
(2005). Benefit of Hepatitis C Virus Core Antigen Assay in Prediction of Therapeutic Response to Interferon and Ribavirin Combination Therapy. J. Clin. Microbiol.
43: 186-191
[Abstract][Full Text]
Rocca, L. G., Yawn, B. P., Wollan, P., Kim, W. R.
(2004). Management of Patients With Hepatitis C in a Community Population: Diagnosis, Discussions, and Decisions to Treat. Ann Fam Med
2: 116-124
[Abstract][Full Text]
Li, Y., Zhang, T., Douglas, S. D., Lai, J.-P., Xiao, W.-D., Pleasure, D. E., Ho, W.-Z.
(2003). Morphine Enhances Hepatitis C Virus (HCV) Replicon Expression. Am. J. Pathol.
163: 1167-1175
[Abstract][Full Text]
Ramos-Casals, M., Trejo, O., Garcia-Carrasco, M., Font, J.
(2003). Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology (Oxford)
42: 818-828
[Full Text]
Reddy, S. I., Ukomadu, C.
(2003). Viral Hepatitis and Hepatocellular Carcinoma in African Americans. Cancer Epidemiol. Biomarkers Prev.
12: 248S-251
[Full Text]
Osborn, B. L., Olsen, H. S., Nardelli, B., Murray, J. H., Zhou, J. X. H., Garcia, A., Moody, G., Zaritskaya, L. S., Sung, C.
(2002). Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-alpha Fusion Protein in Cynomolgus Monkeys. J. Pharmacol. Exp. Ther.
303: 540-548
[Abstract][Full Text]
Cheney, I. W., Lai, V. C. H., Zhong, W., Brodhag, T., Dempsey, S., Lim, C., Hong, Z., Lau, J. Y. N., Tam, R. C.
(2002). Comparative Analysis of Anti-Hepatitis C Virus Activity and Gene Expression Mediated by Alpha, Beta, and Gamma Interferons. J. Virol.
76: 11148-11154
[Abstract][Full Text]
Wang, T. Y., Kuo, H. T., Chen, L. C., Chen, Y. T., Lin, C. N., Lee, M. M.
(2002). Use of Polymerase Chain Reaction for Early Detection and Management of Hepatitis C Virus Infection after Needlestick Injury. Annals of Clinical & Laboratory Science
32: 137-141
[Abstract][Full Text]
Yovtcheva, S. P., Rifai, M. A., Moles, J. K., Van Der Linden, B. J.
(2001). Psychiatric Comorbidity Among Hepatitis C-Positive Patients. Psychosomatics
42: 411-415
[Abstract][Full Text]
Lauer, G. M., Walker, B. D.
(2001). Hepatitis C Virus Infection. NEJM
345: 41-52
[Full Text]
Bethune, C A, Gompels, M M, Taylor, C, Angus, B, Spickett, G P
(2001). Treatment of EBV driven lymphoproliferation with erythrophagocytosis: 12 year follow up. J. Clin. Pathol.
54: 328-331
[Abstract][Full Text]
Bonacini, M., Puoti, M.
(2000). Hepatitis C in Patients With Human Immunodeficiency Virus Infection: Diagnosis, Natural History, Meta-analysis of Sexual and Vertical Transmission, and Therapeutic Issues. Arch Intern Med
160: 3365-3373
[Abstract][Full Text]
Campistol, J. M., Esforzado, N., Martinez, J., Rosello, L., Veciana, L., Modol, J., Casellas, J., Pons, M., de las Cuevas, X., Piera, J., Oliva, J. A., Costa, J., Barrera, J. M., Bruguera, M.
(1999). Efficacy and tolerance of interferon-{alpha}2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant
14: 2704-2709
[Abstract][Full Text]
Vogt, M., Lang, T., Frosner, G., Klingler, C., Sendl, A. F., Zeller, A., Wiebecke, B., Langer, B., Meisner, H., Hess, J.
(1999). Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor Screening. NEJM
341: 866-870
[Abstract][Full Text]
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F., Yokosuka, O., Kinoyama, S., Yamada, G., Omata, M., for the IHIT Study Group,
(1999). Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan. ANN INTERN MED
131: 174-181
[Abstract][Full Text]
Cresta, P, Musset, L, Cacoub, P, Frangeul, L, Vitour, D, Poynard, T, Opolon, P, Nguyen, D-T, Golliot, F, Piette, J-C, Huraux, J-M, Lunel, F
(1999). Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut
45: 122-128
[Abstract][Full Text]
Balfour, H. H.
(1999). Antiviral Drugs. NEJM
340: 1255-1268
[Full Text]
Trinh, L., Ziegler, R., Watling, D., Snider, R. M., Croze, E.
(1999). Development of an Immunofluorometric, High-Capacity, Cell-Based Assay for the Measurement of Human Type I and Type II Interferons. J Biomol Screen
4: 33-37
[Abstract]
Wong, J. B., Bennett, W. G., Koff, R. S., Pauker, S. G.
(1998). Pretreatment Evaluation of Chronic Hepatitis C: Risks, Benefits, and Costs. JAMA
280: 2088-2093
[Abstract][Full Text]
Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., Albrecht, J., The International Hepatitis Interventional Therapy,
(1998). Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. NEJM
339: 1493-1499
[Abstract][Full Text]
Polyak, S. J., McArdle, S., Liu, S.-L., Sullivan, D. G., Chung, M., Hofgartner, W. T., Carithers, R. L. Jr., McMahon, B. J., Mullins, J. I., Corey, L., Gretch, D. R.
(1998). Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection. J. Virol.
72: 4288-4296
[Abstract][Full Text]
Hayashi, J., Kishihara, Y., Ueno, K., Yamaji, K., Kawakami, Y., Furusyo, N., Sawayama, Y., Kashiwagi, S.
(1998). Age-Related Response to Interferon Alfa Treatment in Women vs Men With Chronic Hepatitis C Virus Infection. Arch Intern Med
158: 177-181
[Abstract][Full Text]
Hoofnagle, J. H., Di Bisceglie, A. M.
(1997). The Treatment of Chronic Viral Hepatitis. NEJM
336: 347-356
[Full Text]
Hoofnagle, J. H., Lau, D.
(1996). Chronic Viral Hepatitis -- Benefits of Current Therapies. NEJM
334: 1470-1471
[Full Text]
Dusheiko, G M, Khakoo, S, Soni, P, Grellier, L
(1996). Fortnightly Review: A rational approach to the management of hepatitis C infection. BMJ
312: 357-364
[Abstract][Full Text]
Di Bisceglie, A. M., Conjeevaram, H. S., Fried, M. W., Sallie, R., Park, Y., Yurdaydin, C., Swain, M., Kleiner, D. E., Mahaney, K., Hoofnagle, J. H.
(1995). Ribavirin as Therapy for Chronic Hepatitis C: A Randomized, Double-Blind, Placebo-Controlled Trial. ANN INTERN MED
123: 897-903
[Abstract][Full Text]
Matsumori, A., Matoba, Y., Sasayama, S.
(1995). Dilated Cardiomyopathy Associated With Hepatitis C Virus Infection. Circulation
92: 2519-2525
[Abstract][Full Text]
Kay, M. H., Wyllie, R.
(1995). Therapeutic Applications of Alpha Interferon for Chronic Viral Hepatitis in Pediatric Patients. CLIN PEDIATR
34: 372-379
Gerberding, J. L.
(1995). Management of Occupational Exposures to Blood-Borne Viruses. NEJM
332: 444-451
[Full Text]
Farci, P., Mandas, A., Coiana, A., Lai, M. E., Desmet, V., Van Eyken, P., Gibo, Y., Caruso, L., Scaccabarozzi, S., Criscuolo, D., Ryff, J.-C., Balestrieri, A.
(1994). Treatment of Chronic Hepatitis D with Interferon Alfa-2a. NEJM
330: 88-94
[Abstract][Full Text]
Di Bisceglie, A. M.
(1994). Interferon Therapy for Chronic Viral Hepatitis. NEJM
330: 137-138
[Full Text]
Johnson, R. J., Gretch, D. R., Yamabe, H., Hart, J., Bacchi, C. E., Hartwell, P., Couser, W. G., Corey, L., Wener, M. H., Alpers, C. E., Willson, R.
(1993). Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus Infection. NEJM
328: 465-470
[Abstract][Full Text]
Gorman, S. E., Plaisance, K.
(1991). Application of Products Produced Through Biotechnology in Infectious Diseases. Journal of Pharmacy Practice
4: 103-116
(1989). INTERFERON ALPHA FOR CHRONIC HEPATITIS C. JWatch General
1989: 3-3
[Full Text]
Previous
